anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The present invention is a foundational video architecture and a framework for collecting surgical video at an enterprise scale. It enables hospitals to ingest, manage, and fully utilize patient surgical video within the hospital and to share video with designated users outside of the hospital. It is a passive solution that automatically records video during surgery and provides key clips post-surgery. It stores video to the cloud and integrates videos to the patient&#39;s Electronic Health Record (EHR). The present invention pertains to the need to precisely identify and communicate a specific position on tissue or an organ with a Virtual Pointing Device (VPD) software tool. The VPD uses a combination of audio key words and the surgeon&#39;s hand movements to invoke various functionality.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a polypeptide capable of being used as a diabetes specific marker.  &lt;P&gt;SOLUTION: In relation to prediabetes, diabetes, or susceptibility to diabetes, the polypeptide, capable of being used as a marker for diagnosing susceptibility or predisposing factors to prediabetes, diabetes, or the crisis of diabetes is provided. There is also provided a method for diagnosing susceptibility to prediabetes, diabetes, and/or susceptibility to diabetes by a stage for acquiring biological samples and a stage for detecting and/or measuring the increase of one or a plurality of polypeptides to be disclosed in this specifications. A screening method, related to an agonist and antagonist of a specific polypeptide to be disclosed in the specifications, Antibodies may be produced to the polypeptide markers for detecting and/or treating diabetes. Proteins, protein fragments, or peptides may be used for treating diabetes or prediabetes.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
The present invention provides novel compositions for the delivery of a hypnotic agent across the oral mucosa. In particular, the buffer system in the compositions of the present invention raises the pH of saliva to a pH greater than about 7.8, thereby facilitating the substantially complete conversion of the hypnotic agent from its ionized to its un- ionized form. As a result, the dose of hypnotic agent is rapidly and efficiently absorbed by the oral mucosa with surprisingly low inter- subject variability. Furthermore, delivery of the hypnotic agent across the oral mucosa advantageously bypasses hepatic first pass metabolism of the drug and avoids enzymatic degradation of the drug within the gastrointestinal tract. Methods for using the compositions of the present invention for treating sleep disorders such as insomnia are also provided. ® KIPO &amp; WIPO 2007
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a medicine, a health food and a nutritional medicine composition each of which can improve the oral absorption of glucosaminoglycan or its salt, can enhance its original medicinal effects, and quickly exhibits the effects.  &lt;P&gt;SOLUTION: The oral administration medicine, health food or nutritional medicine composition is characterized by comprising one or more compounds selected from the group consisting of glucosaminoglycan or its salts and one or more compounds selected from the group consisting of saponin and its salts. The glucosaminoglycan or its salts include hyaluronic acid, hyaluronate, dermatan sulfuric acid, dermatan sulfate, chondroitin, chondroitin sulfuric acid, and chondroitin sulfate. The saponin is preferably soybean saponin. The mass ratio of one or more compounds selected from the group consisting of glucosaminoglycan and its salts: one or more compounds selected from the group consisting of saponin and its salts is preferably 1:0.0001 to 2.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
The present invention provides a substantially purified carbohydrate ligand that specifically binds to a leczyme. The invention also provides methods to identify a carbohydrate ligand that specifically binds to a leczyme or a leczyme that specifically binds to a carbohydrate ligand. The invention further provides methods to identify a peptide that binds to the carbohydrate ligand binding site of a leczyme. 
     The present invention provides methods to isolate a carbohydrate ligand or a leczyme and to identify a carbohydrate ligand or a leczyme that modifies the function of a cell and to obtain such functionally modified cells. The invention further provides methods to modify a cell to express a carbohydrate ligand by introducing an expression vector encoding a leczyme into the cell. The invention also provides methods to modulate the immune response to an antigen by administering the antigen and a carbohydrate ligand. In addition, the invention further provides methods to treat a disease state involving a leczyme by administering a carbohydrate ligand that binds the leczyme or by administering a leczyme that has a similar binding specificity to the leczyme involved in the disease state. The invention further provides methods to diagnose a genetic basis for hemochromatosis by detecting a mutation in a class I MHC molecule that reduces it&#39;s ability to associate with β 2  microglobulin.
Techniques related to vision correction are disclosed. The techniques involve establishing a visual model associated with a patient. The visual model includes data related to a quality of the patient&#39; s vision. A boundary is established as a function of the data associated with the visual model. The boundary is indicative of an area to be corrected within the patient&#39;s vision. A retinal map is established as a function of the boundary. An image from a camera associated with the patient is captured and corrections are applied to the image based on the retinal map to generate a corrected image. The corrected image is presented to the eye of the patient.
The oxidizing-agents referred to in Specification 464,857 are added to materials, even when they do not contain proteolytic enzymes, but contain substances or principles promoting the action of enzymes, for instance, co-enzymes, activators, kinases or complements.  These substances or principles are normally able to act on proteolytic enzymes, but, when treated with the oxidizing-agents, are inhibited. Specification 464,857 as open to inspection under Sect. 91 describes the treatment of dry yeast with the oxidizing-agents.  It is now suggested that the inhibition of the proteolytic activity in the dought is due to the inhibition of the co-enzymes &amp;c.ALSO:The oxidizing-agents referred to in Specification 464,857 are added to materials, even when they do not contain proteolytic enzymes, but contain substances or principles promoting the action of enzymes, for instance, co-enzymes, activators, kinases or complements.  These substances or principles are normally able to act on proteolytic enzymes, but, when treated with the oxidizing-agents, are inhibited. Specification 464,857 as open to inspection under Sect. 91 describes the treatment of dry yeast with the oxidizing-agents.  It is now suggested that the inhibition of the proteolytic activity in the dough is due to the inhibition of the co-enzymes &amp;c.
An improved method of inducing protective immunity to the Human Immunodeficiency Virus through isolating a person&#39;s antigen-presenting cells from blood, then pulsing these cells with short peptides that bind the person&#39;s Class I Major Histocompatibility Complex Types and correspond to conserved segments of the HIV structural and functional genes. These pulsed dendritic cells are then injected intravenously, where they will travel to lymph tissue and prime HIV-specific Cytotoxic T Lymphocytes. The immune system is then activated by injecting the person with a weakened arbovirus, Chikungunya. The interferons and other immune-activating chemicals induced by the virus will stimulate creation of billions of killer cells that recognize HIV proteins, allowing for rapid mobilization of memory immune cells to contain and eliminate any subsequent infection with the HIV virus. The vaccine is custom-designed to each person and uses no HIV virus for safety purposes. It is understood that the examples an embodiments described herein are for illustrative purposes only and various changes or modifications in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims.
PURPOSE:To obtain a rapidly breakable hydrous foaming agent which needs no vibration when used and is excellent in low-temp. stability, by mixing a silicone oil with an electron acceptor oil and filling an aerosol container having a particular valve with the mixture together with a propellant. CONSTITUTION:An anhydrous foaming agent is prepd. by enclosing a stock solution contg. a silicone oil, an electron acceptor oil and a propellant in a pressure-resistant can provided with a valve having a stem diameter of 0.33-0.61mm, a housing port diameter of 0.64-2.06mm and a spout having a nozzle area of 2.5-30mm&lt;2&gt;. It is pref. to prepare the above anhydrous foaming agent by blending 5-50wt% silicone oil, 30-80wt% oil, and 15-35wt% propellant. A preferable example of the oil includes fatty acid esters, particularly a triglyceride of a fatty acid.
FIELD: food industry. ^ SUBSTANCE: invention is referred to feeding stuff production. Composition for fatty tissue dissimilation speed-up, fatty acids oxidation speed-up or reduce of fatty tissue dissimilation contains one or more isoflavones or its metabolites and conjugated linoleic acid (CLA) or/and L-carnitine. All components are taken in certain daily quantity. Composition is used to keep animal&#39;s muscle bulk, to reduce tissue injury connected to adiposity. ^ EFFECT: invention allows to obtain composition which can promote reduce of fat depots, reduce muscle bulk losses and reduce injuries related to oxidative stress. ^ 35 cl, 12 dwg, 2 ex
B-Cell malignancies, such as the B-cell subtype of non-Hodgkin&#39;s lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.
PURPOSE:A human monocyte strain producing constantly interleukin-1, capable of being cultivated. CONSTITUTION:Peripheral blood of uncured patient of leukemia is collected in addition of heparin, a monocyte is separated by specific gravity centrifugal method and transferred to a liquid culture system. It is diluted with a culture solution, cultivated in the presence of CO2 at 37 deg.C in a wetting chamber for 1-2hr and floating cells are collected. Then, they are washed and resuspended in the same culture solution. After existence of &gt;=90% leukocyte floating cells is observed by Wright and Giemas dyeing and existence of &gt;=98% live cell number is observed by erythromycin B dyestuff, 0.2ml of the suspension is partially added to 96 hole microplate, cultivated at 37 deg.C in the presence of CO2 in a wetting chamber, half amount of the culture solution is changed two or three days apart and the suspension is cultivated. The culture solution which is observed to have cell multiplication is transferred to a culture system, a cell strain capable of being subjected to subculture is established and cloning is repeated, to give cloned cell strain JOSK-1.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, dentistry and can be used for treatment of inflammatory periodontal diseases. Luminol-dependent chemiluminescence of oral fluid is carried out. Rate of maximum flash and glow light sum is estimated. With the value of maximum flash from 0.8 to 5 c.u. (conventional units) and light sum of 1.5 to 37 c.u. an impact of magneto-infrared laser radiation is conducted. The impact is conducted with a pulse repetition rate of 80 Hz, LED radiating power of 90 mW. The impact is conducted in area of projection of the foci and in field of angle of the mandible on the same side with exposure 2 minutes per point, and then in the spinous process of third cervical vertebra during 1 minute and in oral tissues for 2 minutes. After that it is affected with magneto-infrared laser radiation with frequency of 150 Hz, LED radiating power of 50 mW. The impact is conducted on reflex points GI4 and E36 symmetrically, VC12 or MC6 and RP6 symmetrically, VC12, alternating every other day. At the same time in each session an effect is exerted on points CI 1, GI 20, E 5, V 10. The treatment course is 10 procedures. Exposure is 0.5 minutes on one point. At the maximum flash rate from 6.55 to 25 c.u. and light sum from 26 to 45 c.u. a biologically active food supplement &#34;PropoFlan&#34; is administered in a dose of 2 tablets 3 times a day for 1 month. ^ EFFECT: method provides choice of adequate treatment of inflammatory periodontal diseases taking into account the activity of oxidative processes in oral fluid. ^ 2 ex
Modified polymer collagen hemostatic, having alternate four dimensional structure and high positive charge, was prepared as powder or gel.  Thus, the collagen was extracted from collagen source and polymd. to have 4-dimensional structure of &gt;7,000∦ mol. length, 670-700∦ min. periodicity and 20∦ min. mol. diameter, the obtained polymer was cross-linked and esterified for increasing the positive charge of collagen polymer.
Exposure of colorectal cancer (CRC) cells to ionizing radiation results in a growth arrest, with cells blocked in both the G1 and G2 phases of the cell cycle. The G1 block has been shown to be due to the p53-mediated induction of the cyclin-dependent kinase inhibitor p21&lt;WAF1/CIP1/SDI1&gt;, but the basis for the G2 arrest is unknown. Through a quantitative analysis of gene expression patterns in CRC cell lines, we have discovered that 14-3-3sigma is strongly induced by gamma-irradiation and other DNA-damaging agents. The induction of 14-3-3sigma is mediated by a p53-responsive element located 1.815 kb upstream of its transcription start site. Exogenous introduction of 14-3-3sigma into cycling cells results in a G2 block similar to that observed following irradiation. These results document a molecular mechanism for G2/M control that is regulated in human cells by p53.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a hair-dressing detergent which is normally used before hair washing and a high detergent effect of a hair-dressing agent and its use method.  &lt;P&gt;SOLUTION: The hair-dressing agent detergent comprises a compound (A) having an IOB in the organic concept figure of 0.66-1.5 and an ampholytic surface active agent (B). In the above hair-dressing agent detergent, the ampholytic surface active agent (B) is suitably one or more kinds selected from the group consisting of an alkylbetaine and an amidopropylbetaine. The compounding ratio of (B) to (A) is suitably (B)/(A)=0.01-5.0. The above hair-dressing agent detergent suitably contains a cationic polymer. The use method of the hair-dressing agent detergent comprises coating the above hair-dressing agent on the hair coated with a hair-dressing agent in the state of the hair dried, and washing the hair with water.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain an immunopotentiator free from any side effects and having higher immunopotentiating ability.  &lt;P&gt;SOLUTION: This immunopotentiator comprises, as active ingredients, a cultured product comprising β-1,3-1,6-glucan that is obtained by culturing fungi belonging to Aureobasidium sp. and lactobacillus. In this immunopotentiator, the fungi belonging to Aureobasidium sp. is preferably Aureobasidium pullulans M-1(FERM P-19213) and it is preferable that the lactobacillus is Enterococcus faecalis and has been subjected to heat sterilization.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
An improved method for manufacture of chewing gums containing active ingredient(s) that preserves the efficacy of the active ingredient(s) by avoiding exposure to high heat and extreme cold during milling that can otherwise degrade the active&#39;s efficacy. A chewing gum base is used, along with one or more therapeutically-active ingredients, one or more sweeteners (alcohol-based and/or natural), and one or more flavorings and optional flavor modifiers. The method generally comprises heating the gum base in ovens to melt the gum base. Separately, the active ingredient(s), sweeteners and flavorings are combined in a mixer. The melted gum base is added to the mixer and cools to produce a particulate mixture. As mixing continues the mass cools to room temperature and forms granular pieces. The granular pieces are ground into a powder at room temperature, mixed at room temperature with tableting excipients, and tableted. Several variations on the foregoing are also described.
PURPOSE:To obtain an aqueous coenzyme Q pharmaceutical, containing many ribosomes of a specific amount of lecithin containing a specified amount of dispersed coenzyme Q in an emulsified state, having improved absorbability substantially without ethanol with no limitation on use. CONSTITUTION:One pt.wt. coenzyme Q and 15-100pts.wt. lecithin are dissolved in a solvent capable of dissolving both substances easily, preferably an organic solvent having a dipole moment value &lt;=1.5 (in the liquid phase) and a high volatility or a 3-7C carboxylic ester, and then the solvent is removed. The resultant residue is then emulsified in an aqueous solvent to give an aqueous coenzyme Q pharmaceutical containing many ribosomes of lecithin containing dispersed coenzyme Q in the proportion described above in an emulsified state and substantially no ethanol. The resultant pharmaceutical has improved absorbability in digestive tracts and is useful for the treatment of angina pectoris, etc. by the oral administration.
Systems and methods facilitate information sharing among a plurality of member institutions. Each member is associated with a member number and a corresponding member profile. A member contributes its data relating to small business entities to an exchange repository upon becoming a member, and thereafter on a periodic basis. Each member is eligible to query against the exchange repository. However, a response to a member&#39;s inquiry is determined by a reciprocity due to the inquiring member. Each business entity regarding which information is stored in the exchange repository is associated with a business entity identifier. A business entity identifier associates a record file for the corresponding small business entity. The record file includes trade data of the small business, data relating to one or more principals of the small business entity, as well as data relating to one or more guarantors of the small business entity, as appropriate.
Provided is a derivative of 22-hydroxyeholesterol, 24S-hydroxycholesterol, 25- hydroxycholesterol, 26- hydroxyeholeserol or 27-hydroxyeholesierol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxyeholesterol, 25-hydroxycholesterol 26- hydroxycholesterol or 27- hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22- hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol 26- hydroxycholesterol or 27- hydroxycholesterol is provided. Also, a method of assaying for 22- hydroxycholesterol, 24S- hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27- hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol, 24S- hydroxycholesterol 25- hydroxycholesterol 26- hydroxycholesterol or 27-hydroxycholesterol A method of detecting an enzyme or enzymes utilized in phase II drug metabolism is also provided. Also, a method of detecting an enzyme that synthesizes 22-hydroxycholesterol 24S-hydroxycholesterol, 25- hydroxycholesterol, 26- hydroxycholesterol or 27-hydroxycholesterol is provided. Further provided is a method of evaluating progression of multiple sclerosis in a patient. Also provided is a method of determining whether a treatment for multiple sclerosis in a patient is effective. Further, a method, of evaluating progression of Huntington&#39;s disease in a patient is provided. Additionally provided is a method of determining whether a treatment for Huntington&#39;s disease in a patient is effective.
1,146,486. Osteoblastic extract. SOC. D&#39;ETUDES ET DE RECHERCHES BIOLOGIQUES. 24 June, 1966, No. 28516/66. Heading A5B. An osteoblastic extract for use in the treatment of bone affections is obtained by extracting comminuted endochondral tissue from the long bones of sexually immature mammals first with a neutral aqueous liquid, secondly with an alkaline aqueous liquid of pH 8-11, and thirdly with an acidic aqueous liquid of pH 3-6, storing separately) the aqueous liquids from each extraction for at least 4 hours at low temperature, combining the three extracts, adjusting the pH of the combined extracts to neutrality if necessary, removing undissolved solids, and lyophilizing the remaining liquid. The extracts may be administered in the form of an ointment or cream, optionally with hyaluronidase, or suppositories or an injectable solution.
PURPOSE:To obtain a bathing agent composition which is excellent in the humectant effect on skin and inhibits skin dryness and roughness, moreover sustains moisture retention effect on skin after bathing. CONSTITUTION:This bathing agent composition comprises at least one of monoesters between cholesterol and a dicarboxylic acid of the formula (R&lt;1&gt; is a 2-20C straight or branched alkylene or alkenylene; R&lt;2&gt; is a residue after OH proton is removed from cholesterol), for example, cholesteryl hemimaleate or cholesteryl hemisuccinate in an amount of 0.01-50wt.%, particularly 0.1-10wt.%. When an antiinflammatory agent is incorporated into this composition, anti-itching effect becomes stronger than in the case of its single application after bathing. The antiinflammatory agent is preferably rice bran oil, german chamomile essence or dipotassium glycyrrhizinate, in the meaning of controlling skin itching. The amount of these antiinflammatory agents is particularly preferably 0.1-5wt.%. This composition may also contain other oil components than the monoester stated above and a dispersion emulsifier for these oil components.